Neflamapimod + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Moderate to Severe Acute Ischaemic Stroke
Conditions
Moderate to Severe Acute Ischaemic Stroke, Ischaemic Stroke
Trial Timeline
Jun 20, 2025 → Jun 28, 2026
NCT ID
NCT06987643About Neflamapimod + Placebo
Neflamapimod + Placebo is a phase 2 stage product being developed by CervoMed for Moderate to Severe Acute Ischaemic Stroke. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06987643. Target conditions include Moderate to Severe Acute Ischaemic Stroke, Ischaemic Stroke.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07033481 | Phase 2 | Recruiting |
| NCT06987643 | Phase 2 | Recruiting |
| NCT05869669 | Phase 2 | Completed |
Competing Products
20 competing products in Moderate to Severe Acute Ischaemic Stroke